Guggenheim Forecasts Strong Price Appreciation for Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences (NASDAQ:ROIV) had its target price boosted by analysts at Guggenheim from $36.00 to $42.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Guggenheim’s price target suggests a potential upside of 16.33% from the company’s previous close.

A number of other research firms have also weighed in on ROIV. Bank of America restated a “neutral” rating on shares of Roivant Sciences in a research note on Friday, July 31st. HC Wainwright upped their target price on shares of Roivant Sciences from $34.00 to $41.00 and gave the stock a “buy” rating in a research note on Friday. Piper Sandler reiterated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. Sanford C. Bernstein raised shares of Roivant Sciences to a “strong-buy” rating in a research report on Wednesday, July 29th. Finally, Leerink Partners set a $42.00 price objective on shares of Roivant Sciences in a report on Thursday, May 21st. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $34.77.

Roivant Sciences Stock Performance

Shares of ROIV traded up $0.98 during trading hours on Friday, hitting $36.10. The company had a trading volume of 2,747,517 shares, compared to its average volume of 5,919,824. The stock has a market capitalization of $25.97 billion, a price-to-earnings ratio of -60.14 and a beta of 1.12. The firm has a fifty day moving average price of $33.00 and a 200-day moving average price of $29.41. Roivant Sciences has a 52-week low of $10.90 and a 52-week high of $37.00.

Insiders Place Their Bets

In other news, Director Melissa B. Epperly sold 17,750 shares of Roivant Sciences stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $34.38, for a total value of $610,245.00. Following the completion of the sale, the director directly owned 16,474 shares in the company, valued at $566,376.12. The trade was a 51.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daniel Allen Gold sold 800,000 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $34.55, for a total transaction of $27,640,000.00. Following the transaction, the director directly owned 13,701,546 shares of the company’s stock, valued at $473,388,414.30. The trade was a 5.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 2,055,913 shares of company stock valued at $69,639,633. 8.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Roivant Sciences

Large investors have recently added to or reduced their stakes in the stock. SBI Securities Co. Ltd. raised its stake in Roivant Sciences by 1,740.3% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after buying an additional 1,166 shares during the last quarter. Allworth Financial LP boosted its stake in shares of Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after buying an additional 583 shares during the last quarter. Parallel Advisors LLC grew its holdings in shares of Roivant Sciences by 33.7% in the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after acquiring an additional 520 shares during the period. Kestra Advisory Services LLC bought a new stake in shares of Roivant Sciences in the fourth quarter worth $47,000. Finally, Bessemer Group Inc. increased its position in Roivant Sciences by 21.8% during the first quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock valued at $69,000 after acquiring an additional 441 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.